Enteric coated tablets
The male prostate or prostate gland is an accessory sex gland that produces part of the semen. It has roughly the shape of a chestnut and covers the beginning of the urethra down to the pelvic floor. The back of the prostate borders on the rectum and can also be felt from there. Like all glandular organs in humans, the prostate is well supplied with blood and hormonally regulated. In particular, an increased content of dihydrotestosterone (DHT), which is produced from testosterone with the help of the enzyme 5-alpha-reductase and has a strong androgenic effect, is considered to be the main cause of prostate hyperplasia.
Benign prostatic hyperplasia, also known as BPH, is a benign enlargement or growth of prostate tissue that in most cases leads to clinical symptoms. Depending on the severity, this is divided into three stages (according to Alken). While stage I and II diseases can usually still be treated with medication, stage III usually requires surgery. There are many clinical symptoms of BPH, mostly urinary disorders with symptoms such as frequent urination, increased urinary flow, thin urinary stream, dribbling, pain when urinating through to urinary retention. The primary goal of treatment is therefore to eliminate the obstruction and prevent recurring urinary tract infections.
Eviprostat N is an oral medication for the treatment of urinary symptoms in the context of benign prostatic hyperplasia (BPH) stages I and II according to Alken. In Eviprostat N, four of the best-known and most proven urologically effective medicinal plants are combined into a combination preparation whose effectiveness has not only been proven through many years of experience, but also through experimental investigations and clinical studies. The medicinal plants Chimaphila umbellata (umbelliferous wintergreen) , Equisetum arvense ( horsetail ), Pulsatilla pratensis ( pasque flower or small pasque flower) and Populus tremuloides (aspen or aspen) are combined in Eviprostat N.
Pasque flower, field horsetail, wintergreen and aspen extracts have been shown to have flushing (diuretic) and/or antiseptic properties that help reduce the risk of UTIs. In addition, aspen and field horsetail extracts have anti-oedematous and anti-inflammatory (anti-inflammatory) effects that lead to a reduction in swelling (stasis oedema) in the lower urinary tract. These effects can be attributed to the components of the plants such as flavonoids, in particular quercetin, luteolin and kaempferol, but also ursolic acid, chimaphilin, arbutin and those from Populus tremuloides originating salicylic acid derivatives. The flavonoids in particular, but also some isolated mono-substances, have recently been examined in detail with regard to their pharmacological and pharmacodynamic effects and the anti-inflammatory, diuretic and antiseptic effects have been confirmed.
Several experimental findings (in vitro and in vivo) support the plausibility of using the Eviprostat N combination in BPH:
Beneficial effects in patients with lower urinary tract symptoms (LUTS) in mild and moderate BPH related to urinary symptoms, particularly weakness in urinary flow, dysuria (pain or difficulty urinating), pollakiuria (abnormally frequent urination) and nocturia (nocturnal urinary frequency). ),
Improvement in objective parameters such as micturition frequency, urinary retention volume and prostate size under eviprostat N treatment
BPH (not too poor physical functioning) patients showed a significantly greater drop in IPSS score of 23.5% in the eviprostat group compared to the placebo group.
Safety Results: Well tolerated, with rare, non-serious gastrointestinal complaints in some patients
The pharmacological and clinical study results as well as the therapeutic experience from more than 60 years of medical use, supported by bibliographic data, confirm the effects and clinical effectiveness of Eviprostat N for the indication.
Against the background of the multifactorial pathogenesis of BPH, the use of a "multi-component mixture of 5 specific plant extracts", such as Eviprostat N, with different pharmacodynamic targets, is scientifically plausible and sensible for the indication. With the 5-way combination of Eviprostat N, additive effects together with other synergistic effects can be assumed - as explained above for the flavonoids contained simultaneously in several individual extracts.
Pasque flower, field horsetail, wintergreen and aspen extracts have been shown to have flushing (diuretic) and/or antiseptic properties that help reduce the risk of UTIs. In addition, aspen and field horsetail extracts have anti-oedematous and anti-inflammatory (anti-inflammatory) effects that lead to a reduction in swelling (stasis oedema) in the lower urinary tract. These effects can be attributed to the components of the plants such as flavonoids, in particular quercetin, luteolin and kaempferol, but also ursolic acid, chimaphilin, arbutin and those from Populus tremuloidesoriginating salicylic acid derivatives. The flavonoids in particular, but also some isolated mono-substances, have recently been examined in detail with regard to their pharmacological and pharmacodynamic effects and the anti-inflammatory, diuretic and antiseptic effects have been confirmed.
Inhibition of inflammation and suppression of reactive oxygen species (ROS), markers of urinary oxidative stress and pro-inflammatory cytokine levels
Areas of application:
To improve urinary symptoms in the case of benign enlargement of the prostate (prostate gland) in older men. Before use, serious illnesses must be ruled out by a doctor.
Eviprostat N is a traditional medicinal product that is registered for the area of application solely because it has been used for many years.
Contains sucrose, lactose and glucose.
For risks and side effects, read the leaflet and ask your doctor or pharmacist.
| designation | Crowd |
|---|---|
| Chimaphila umbellata (Tinct.) | 0.5 mg |
| Equisetum arvense unspecified (Extr.sicc.) | 1.5 mg |
| Populus tremuloides (Tinct.) | 0.5 mg |
| Pulsatilla pratensis unspecified (Tinct.) | 0.5 mg |